All In Biotech

Drug Trial Radar · NCT05779163

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Apr 14, 2023

Primary completion

Apr 3, 2025

Study completion Apr 3, 2025

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
First posted
Mar 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

Conditions

  • Advanced Malignant Tumors

Interventions

  • LBL-033 for InjectionDrug

    Initial dose - MTD; Q2W; intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities(DLT)Time frame: At the end of Cycle 1(28 days after the first prespecified dose)
  2. Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1(28 days after the first prespecified dose)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • West China Second University Hospital,Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.